Stocks and Investing
Stocks and Investing
Wed, July 12, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jonathan Wolleben Reiterated (ALT) at Buy and Held Target at $15 on, Jul 12th, 2023
Jonathan Wolleben of JMP Securities, Reiterated "Altimmune, Inc." (ALT) at Buy and Held Target at $15 on, Jul 12th, 2023.
Jonathan has made no other calls on ALT in the last 4 months.
There are 2 other peers that have a rating on ALT. Out of the 2 peers that are also analyzing ALT, 1 agrees with Jonathan's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Corinne Jenkins of "Goldman Sachs" Downgraded from Strong Buy to Hold and Decreased Target to $6 on, Wednesday, March 22nd, 2023
This is the rating of the analyst that currently disagrees with Jonathan
- Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $50 on, Monday, May 15th, 2023
Contributing Sources